Delivery Order SPE2DB24D2012-SPE2DB26FBUPE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Lamotrigine ER 50 mg tablets in quantities of 30 units, valued at $6,761.68. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. The contract is scheduled for completion by October 24, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Lamotrigine ER 200 mg tablets in a 30-count package, with a ceiling value of $1,516.80 and a firm fixed price structure. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime contract vehicle valued through December 2026 that provides...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Lamotrigine ER 250 mg tablets (30-count) with a ceiling value of $1,185.40. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 26, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,426.01 to AmerisourceBergen Drug Corp for Lamotrigine ER 300 mg tablets (30-count) on September 24, 2025, with completion scheduled for September 25, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and is performed at the contractor's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $3,943.17 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lamotrigine ER 250 mg tablets (30-count units), with an ultimate completion date of August 13, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $1,119.28 to AmerisourceBergen Drug Corp for Lamotrigine ER 300 mg tablets (30-count) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price, competitively awarded delivery order will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is executed under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lamotrigine ER 300 mg tablets (30-count) under a firm fixed price contract valued at $1,471.86. The delivery order, issued on May 8, 2025, with an ultimate completion date of May 9, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency has awarded a delivery order valued at $1,638.18 to AmerisourceBergen Drug Corp for the supply of Lamotrigine ER 250 mg tablets in quantities of 30 units. The contract is structured as a firm fixed price delivery order with an ultimate completion date of June 2, 2025. This award was made through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Lamotrigine ODT 200 mg tablets in quantities of 30 units, with a ceiling value of $6,988.90. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract calls for performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August...
- The Defense Logistics Agency awarded a delivery order valued at $1,336.23 to AmerisourceBergen Drug Corp for Lamotrigine ER 300 mg tablets (30-count supply) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Lamotrigine is a neurological medication commonly used to treat epilepsy and bipolar...
- SPE2DB24D2012Indefinite Delivery Contract
- SPE2DB24D2012-SPE2DB26FBUPEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Lamotrigine ER 300 mg tablets (30-count units) valued at $1,750.97. This competitive, non-set-aside delivery order is categorized as firm fixed price and is scheduled for completion by October 28, 2025, with performance at the contractor's Conshohocken, Pennsylvania headquarters. The award represents a continuation of AmerisourceBergen's significant role in supporting federal pharmaceutical procurement, particularly through the Defense Health Agency and military healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.99 billion through December 2026. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive portfolio of federal contracts covering a broad spectrum of medications and medical supplies across multiple therapeutic domains. The firm's demonstrated capability to fulfill competitive federal medical procurement requirements, combined with its prime vendor status for global pharmaceutical support, positions it as a critical supplier for military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 10/27/25 |